Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.
Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, Guardigli G, Parrinello G, Malagutti P, Soukhomovskaia O, Bettini A, Campo G, Ferrari R. Valgimigli M, et al. Among authors: cicchitelli g. Cardiovasc Drugs Ther. 2004 May;18(3):225-30. doi: 10.1023/B:CARD.0000033644.91126.f7. Cardiovasc Drugs Ther. 2004. PMID: 15229391 Clinical Trial.
Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction.
Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, Canistro D, Francolini G, Macrì G, Mastrorilli F, Paolini M, Ferrari R. Valgimigli M, et al. Among authors: cicchitelli g. J Am Coll Cardiol. 2004 Jun 2;43(11):2000-8. doi: 10.1016/j.jacc.2004.01.036. J Am Coll Cardiol. 2004. PMID: 15172404 Free article.
Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study.
Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Valgimigli M, et al. Among authors: cicchitelli g. Circulation. 2005 Feb 22;111(7):863-70. doi: 10.1161/01.CIR.0000155614.35441.69. Epub 2005 Feb 7. Circulation. 2005. PMID: 15699251
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators. Valgimigli M, et al. Among authors: cicchitelli g. JAMA. 2005 May 4;293(17):2109-17. doi: 10.1001/jama.293.17.2109. JAMA. 2005. PMID: 15870414 Clinical Trial.
Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.
Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Campo G, et al. Among authors: cicchitelli g. J Am Coll Cardiol. 2006 Dec 5;48(11):2178-85. doi: 10.1016/j.jacc.2005.12.085. Epub 2006 Nov 13. J Am Coll Cardiol. 2006. PMID: 17161242 Free article.
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
De Luca L, Formigli D, Meessen J, Uguccioni M, Cosentino N, Paolillo C, Di Lenarda A, Colivicchi F, Gabrielli D, Gulizia MM, Scherillo M; START Investigators. De Luca L, et al. Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):513-520. doi: 10.1093/ehjqcco/qcaa054. Eur Heart J Qual Care Clin Outcomes. 2021. PMID: 32559279
11 results